Dilution analysis demonstrated that, although the lower FLT3+ ratios required longer period to repopulate, even those with extremely low numbers of FLT3+ CML cells were sufficient to eventually replace the whole population after acquiring imatinib resistance (Fig. 1K and L, S1F). This evidence concerns the gene FLT3 and chronic myelogenous leukemia, BCR-ABL1 positive.